(Q33533630)

27 July 2017

Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment (English)

1 reference

27 July 2017

1 reference

1 reference

Sergey V Tokalov

1

0 references

author name string

Nasreddin D Abolmaali

series ordinal

2

1 reference

PubMed ID

20178585

27 July 2017

language of work or name

English

0 references

publication date

23 February 2010

1 reference

27 July 2017

1 reference

27 July 2017

10

1 reference

27 July 2017

57

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-10-57

27 July 2017

0 references

cites work

Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

RNA interference-mediated validation of genes involved in telomere maintenance and evasion of apoptosis as cancer therapeutic targets.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis and sensitizes lung cancer cells to chemotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Targeting cell signaling pathways for drug discovery: an old lock needs a new key.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Varying responses of human cells with discrepant p53 activity to ionizing radiation and heat shock exposure

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Multi-target therapeutics: when the whole is greater than the sum of the parts

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

MDM2 inhibitors for cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

The role of p53 in treatment responses of lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

The transcriptional targets of p53 in apoptosis control

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Microtubule-targeted anticancer agents and apoptosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

5-Fluorouracil: mechanisms of action and clinical strategies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2841137

Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-10-57

Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-10-57

Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-10-57

Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs

21 January 2018

1 reference

12 December 2020

Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers

1 reference

12 December 2020

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

1 reference

12 December 2020

Radiotherapy of lung cancer: technology meets biology meets multidisciplinarity

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-10-57

1 reference

PubMed ID

20178585

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference

PubMed ID

20178585